Jul 16 2015
Melissa Thomas at Boehringer Ingelheim sent a press release about the report of their phase III trial, Idarucizumab for Dabigatran Reversal. The free full text article, Pollack CV, Reliiy PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal, NEJM 2015, DOI: 10.1056/NEJMoa1502000, is available from the NEJM web site.
Comments (0)Anticoagulant Therapy
No comments here.